Compare
Marker Therapeutics, Inc. vs Camp4 Therapeutics Corp vs China Pharma Holdings, Inc. vs TherapeuticsMD, Inc.
| Latest fiscal year | Marker Therapeutics, Inc. MRKR | Camp4 Therapeutics Corp CAMP | China Pharma Holdings, Inc. CPHI | TherapeuticsMD, Inc. TXMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.55M | $3.50M | $4.14M | $3.02M |
| Revenue growth (YoY) | -46.2% | +436.5% | -8.5% | +71.6% |
| Gross margin | n/a | n/a | -3.2% | n/a |
| Operating margin | -363.5% | n/m | -78.2% | -145.3% |
| Net margin | -343.0% | n/m | -76.9% | -18.8% |
| Net income | -$12.16M | -$80.40M | -$3.19M | -$569.0K |
| EPS (Diluted) | -$0.79 | -$2.65 | -$0.74 | -$0.05 |
| Operating cash flow | -$12.01M | -$29.55M | $148.3K | $2.45M |
| Free cash flow | n/a | -$29.83M | $88.9K | n/a |
| Cash & equivalents | $16.07M | $109.52M | $345.1K | n/a |
| Total assets | $19.07M | $117.81M | $31.00M | $37.66M |
| Total liabilities | $2.27M | $70.10M | $8.26M | $10.78M |
| Shareholders' equity | $16.80M | $47.70M | $22.74M | $26.88M |
| Return on year-end equity | -72.4% | -168.5% | -14.0% | -2.1% |
| Shares outstanding | 16.70M | 51.90M | 15.52M | 11.57M |
Revenue, most recent five fiscal years
| Fiscal year | Marker Therapeutics, Inc. | Camp4 Therapeutics Corp | China Pharma Holdings, Inc. | TherapeuticsMD, Inc. |
|---|---|---|---|---|
| Latest | $3.55M Ended 2025-12-31 | $3.50M Ended 2025-12-31 | $4.14M Ended 2025-12-31 | $3.02M Ended 2025-12-31 |
| 1 year earlier | $6.59M Ended 2024-12-31 | $652.0K Ended 2024-12-31 | $4.53M Ended 2024-12-31 | $1.76M Ended 2024-12-31 |
| 2 years earlier | $3.31M Ended 2023-12-31 | $350.0K Ended 2023-12-31 | $7.01M Ended 2023-12-31 | $1.30M Ended 2023-12-31 |
| 3 years earlier | $3.51M Ended 2022-12-31 | n/a | $8.10M Ended 2022-12-31 | $69.96M Ended 2022-12-31 |
| 4 years earlier | $1.24M Ended 2021-12-31 | n/a | $9.64M Ended 2021-12-31 | $2.57M Ended 2021-12-31 |